Bioequivalence Test of Gabapentin 800 mg Tablets

가바펜틴 800밀리그람 정제의 생물학적동등성시험

  • Kim, Se-Mi (College of Pharmacy, Institute of Bioequivalence and Bridging Study, Chonnam National University) ;
  • Shin, Sae-Byeok (College of Pharmacy, Institute of Bioequivalence and Bridging Study, Chonnam National University) ;
  • Kang, Hyun-Ah (Pharmaceutical Research Institute, CJ CheilJedong Corp.) ;
  • Cho, Hea-Young (General Pharmacology Team, Pharmacological Research Department, NITR, KFDA) ;
  • Lee, Yong-Bok (College of Pharmacy, Institute of Bioequivalence and Bridging Study, Chonnam National University)
  • 김세미 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소) ;
  • 신새벽 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소) ;
  • 강현아 (CJ제일제당주식회사 제약연구소) ;
  • 조혜영 (국립독성과학원) ;
  • 이용복 (전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소)
  • Published : 2008.08.31

Abstract

Gabapentin, 1-(aminomethyl) cyclohexaneacetic acid, is a amino acid derivative, and is clinically effective in the treatment of neuropathic pain and partial seizures of epilepsy as a complementary therapy. The purpose of the present study was to evaluate the bioequivalence of two gabapentin tablets, $Neurontin^{R}$ tablet 800 mg (Pfizer Pharmaceuticals Co., Ltd.) and Gabapenin tablet 800 mg (Hanmi Pharm. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of gabapentin from the two gabapentin formulations in vitro was tested using KP VIII Apparatus II method with 0.06 M HCI dissolution media. Twenty six healthy male subjects, $23.85{\pm}2.24$ years in age and $69.40{\pm}11.11$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ crossover study was employed. After a single tablet containing 800 mg as gabapentin was orally administered, blood samples were taken at predetermined time intervals and the concentrations of gabapentin in serum were determined using HPLC with fluorescence detector. The dissolution profiles of two formulations were similar in the tested dissolution media. The pharmacokinetic parameters such as $AUC_{t}$, $C_{max}$ and $T_{max}$ were calculated, and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_{t}$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Neurontin^{R}$, were 1.28%, 0.63% and 0.62% for $AUC_{t}$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., $log0.9097{\sim}log1.1598$ and $log0.8919{\sim}log1.1262$ for $AUC_{t}$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Gabapenin tablet 800 mg was bioequivalent to $Neurontin^{R}$ tablet 800 mg.

Keywords

References

  1. Rowbotham, M., Harden, N., Stacey, B., Bernstein, P. and Miller, L. M. : Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280, 1837 (1998) https://doi.org/10.1001/jama.280.21.1837
  2. Blum, R. A., Comstock, T. J., Sica, D. A., Schultz, R. W., Keller, E., Reetze, P., Bockbrader, H., Tuerck, D., Busch, J. A., Reece P. A. and Sedman, A. J. : Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin. Pharmacol. Ther. 56, 154 (1994) https://doi.org/10.1038/clpt.1994.118
  3. Elwes, R. D. C. and Binnie, C. D. : Clinical pharmacokinetics of newer antiepileptic drugs. Clin. Pharmacokinet. 30, 403 (1996) https://doi.org/10.2165/00003088-199630060-00001
  4. 식품의약품안전청 고시 제2005-31호, 생물학적동등성시험기준, 식 품의약품안전청 (2005. 6. 7)
  5. 식품의약품안전청 고시 제1999-67호, 의약품임상시험관리기준, 식 품의약품안전청 (2000. 1. 4)
  6. Tang, P. H., Miles, M. V., Glauser, T. A. and DeGrauw, T. : Automated microanalysis of gabapentin in human serum by high-performance liquid chromatography with fluorometric detection. J. Chromatogr. B 727, 125 (1999) https://doi.org/10.1016/S0378-4347(99)00077-8
  7. Forrest, G., Sills, G. J., Leach, J. P. and Brodie, M. J. : Determination of gabapentin in plasma by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 681, 421 (1996) https://doi.org/10.1016/0378-4347(96)00074-6
  8. Wad, N. and Krämer, G. : Sensitive high-performance liquid chromatographic method with fluorometric detection for the simultaneous determination of gabapentin and vigabatrin in serum and urine. J. Chromatogr. B Biomed. Sci. Appl. 705, 154 (1998) https://doi.org/10.1016/S0378-4347(97)00521-5
  9. 조혜영, 강현아, 박은자, 오세원, 문재동, 이용복 : 뉴론틴 캡슐 300밀리그람(가바펜틴 300 mg)에 대한 건일가바펜틴 캡슐 300밀 리그람의 생물학적동등성. 약제학회지 35, 193 (2005)
  10. Statistical Solutions Ltd., Equiv $Test^{\circledR}$ 2.0, U.K. (2001)
  11. Food and Drug Administration (FDA): Guidance for Industry; Waiver of in vivo bioavailability and bioequivalence study for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, Center for Drug Evaluation and Research (CDER), August (2000)
  12. 김세미, 강현아, 조혜영, 신새벽, 류희두, 윤화, 이용복 : 가바펜 틴 400밀리그람 캡슐의 생물학적동등성시험. 약학회지 52, 195 (2008)